Urosepsis: from the intensive care viewpoint

International Journal of Antimicrobial Agents

Volumn 31, Issue SUPPL. 1, 2008, Pages 79-84

  Marx, G ^a   Reinhart, K ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Diagnosis; Sepsis; Treatment; Urosepsis

Indexed keywords

ACTIVATED PROTEIN C; ALBUMIN; CORTICOSTEROID; FLUDROCORTISONE; HETASTARCH; HYDROCORTISONE; HYPERTENSIVE FACTOR; INOTROPIC AGENT;

ANTIBIOTIC THERAPY; APACHE; ARTICLE; CLINICAL ASSESSMENT; EARLY DIAGNOSIS; FLUID THERAPY; GERMANY; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYDRATION; INTENSIVE CARE; LOW DRUG DOSE; MORTALITY; MULTIPLE ORGAN FAILURE; OXYGEN TRANSPORT; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; TISSUE OXYGENATION; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; GERMANY; HUMANS; HYDROCORTISONE; INTENSIVE CARE; PROTEIN C; SEPSIS; URINARY TRACT INFECTIONS;

EID: 38149003785     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2007.07.014     Document Type: Article

References (40)

1. Brunkhorst F.M. Epidemiology, economy and practice-results of the German study on prevalence by the competence network sepsis (SepNet). Anasthesiol Intensivmed Notfallmed Schmerzther 41 (2006) 43-44 [in German]
2. Reinhart K., Meisner M., and Brunkhorst F.M. Markers for sepsis diagnosis: what is useful?. Crit Care Clin 22 (2006) 503-519
3. Sakka S.G., Reinhart K., and Meier-Hellmann A. Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 122 (2002) 1715-1720
4. Christ-Crain M., Stolz D., Bingisser R., et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174 (2006) 84-93
5. Schuerholz T., Swaraj S., Stallwood M., Nolan J., Leuwer M., and Marx G. Indocyanine green plasma disappearance rate: an indicator for liver dysfunction in sepsis. Infection 33 Suppl. 1 (2005) 33
6. Reinhart K., Brunkhorst F., Bone H., et al. Diagnosis and therapy of sepsis. Guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine. Internist (Berl) 47 (2006) 358-360 362-8 [in German]
7. Kumar A., Roberts D., Wood K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34 (2006) 1589-1596
8. Reinhart K. Oxygen transport and tissue oxygenation in sepsis and septic shock. In: Reinhart K., and Eyrich K. (Eds). Sepsis-an interdisciplinary challenge (1989), Springer, Berlin, Heidelberg, New York, Tokyo 125-133
9. Marshall J.C. Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 29 Suppl. (2001) S99-S106
10. Reinhart K., and Bloos F. The value of venous oximetry. Curr Opin Crit Care 11 (2005) 259-263
11. Harvey S., Harrison D.A., Singer M., et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 366 (2005) 472-477
12. Sakr Y., Vincent J.L., Reinhart K., et al. Use of the pulmonary artery catheter is not associated with worse outcome in the ICU. Chest 128 (2005) 2722-2731
13. Sandham J.D., Hull R.D., Brant R.F., et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 348 (2003) 5-14
14. Rivers E., Nguyen B., Havstad S., et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 (2001) 1368-1377
15. Dellinger R.P., Carlet J.M., Masur H., et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32 (2004) 858-873
16. Hasibeder W.R. Fluid resuscitation during capillary leakage: does the type of fluid make a difference. Intensive Care Med 28 (2002) 532-534
17. Bisonni R.S., Holtgrave D.R., Lawler F., and Marley D.S. Colloids versus crystalloids in fluid resuscitation: an analysis of randomized controlled trials. J Fam Pract 32 (1991) 387-390
18. Schierhout G., and Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ 316 (1998) 961-964
19. Choi P.T., Yip G., Quinonez L.G., and Cook D.J. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 27 (1999) 200-210
20. Velanovich V. Crystalloid versus colloid fluid resuscitation: a meta-analysis of mortality. Surgery 105 (1989) 65-71
21. Finfer S., Bellomo R., Boyce N., French J., Myburgh J., and Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350 (2004) 2247-2256
22. Alderson P., Bunn F., Lefebvre C., et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev (2004) CD001208
23. Vincent J.L., Navickis R.J., and Wilkes M.M. Morbidity in hospitalized patients receiving human albumin: a meta-analysis of randomized, controlled trials. Crit Care Med 32 (2004) 2029-2038
24. Hankeln K., Radel C., Beez M., Laniewski P., and Bohmert F. Comparison of hydroxyethyl starch and lactated Ringer's solution on hemodynamics and oxygen transport of critically ill patients in prospective crossover studies. Crit Care Med 17 (1989) 133-135
25. Boldt J., Heesen M., Muller M., Pabsdorf M., and Hempelmann G. The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically ill patients. Anesth Analg 83 (1996) 254-261
26. Boldt J., Muller M., Heesen M., Heyn O., and Hempelmann G. Influence of different volume therapies on platelet function in the critically ill. Intensive Care Med 22 (1996) 1075-1081
27. Schortgen F., Lacherade J.C., Bruneel F., et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357 (2001) 911-916
28. Marx G., Brunkhorst F.M., and Reinhart K. Intensive insulin therapy in critically ill patients-contra. Dtsch Med Wochenschr 131 (2006) 2481 [in German]
29. Marx G., Pedder S., Smith L., et al. Attenuation of capillary leakage by hydroxyethyl starch (130/0.42) in a porcine model of septic shock. Crit Care Med 34 (2006) 3005-3010
30. Bone R.C., Fisher Jr. C.J., Clemmer T.P., Slotman G.J., Metz C.A., and Balk R.A. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317 (1987) 653-658
31. Annane D., Sebille V., Charpentier C., et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002) 862-871
32. Umpierrez G.E., Isaacs S.D., Bazargan N., You X., Thaler L.M., and Kitabchi A.E. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 87 (2002) 978-982
33. van den Berghe G., Wouters P., Weekers F., et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 345 (2001) 1359-1367
34. Van den Berghe G., Wilmer A., Hermans G., et al. Intensive insulin therapy in the medical ICU. N Engl J Med 354 (2006) 449-461
35. Malhotra A. Intensive insulin in intensive care. N Engl J Med 354 (2006) 516-518
36. Brunkhorst F., Kuhnt E., Engel C., et al. Intensive insulin therapy in patient with severe sepsis and septic shock is associated with an increased rate of hypoglycemia-results from randomized multicenter study (VISEP). Infection 33 Suppl. 1 (2005) 19
37. Russell J.A. Management of sepsis. N Engl J Med 355 (2006) 1699-1713
38. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
39. Abraham E., Laterre P.F., Garg R., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353 (2005) 1332-1341
40. Vincent J.L., Bernard G.R., Beale R., et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33 (2005) 2266-2277